Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune and Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for IRAK1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IRAK1 Kinase Domain (WT & Mutant) Recombinant Protein High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. Theoretical MW confirmed by analytical SEC. |
View IRAK1 Products |
| Gene Delivery | IRAK1 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation. HEK293 expressed backbone. |
View IRAK1 Products |
| Benchmark Ab | Anti-IRAK1 (Sequence Verified) Recombinant Antibody Positive control for Western Blot, IP, and ICC. |
View IRAK1 Products |
| Validator | IRAK1 siRNA Set For knockdown verification and specificity controls in reporter assays. |
View IRAK1 Products |
| IRAK4 | IRAK4 Kinase Domain Protein Paralog kinase for selectivity counter-screens (Critical off-target). |
View IRAK4 Products |
| MYD88 | MYD88 (L265P Mutant Available) Upstream adaptor, recruitment node for IRAK1. |
View MYD88 Products |
| TRAF6 | TRAF6 E3 Ligase Domain Downstream effector, pathway integrity readout. |
View TRAF6 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| IRAK1/IRAK4 Subfamily Selectivity | Human IRAK1 & IRAK4 Kinase Domains available pair-wise with >95% purity; sequence verified for orthogonal off-target profiling |
| Drug Resistance & Mutant Screening | IRAK1 Mutant Recombinant Panel (gatekeeper and activation-loop models e.g. S522F, K239S); high-purity, endotoxin-controlled |
| Lack of Cellular Assay Controls & False Positives | Full-length IRAK1 Lentivirus particles for stable overexpression; IRAK1 siRNA for loss-of-function validation |
| PROTAC Degradation Assays (Full-length conformation needed) | Full-length IRAK1 Protein (1-712 aa) expressed in HEK293 for native folding; suitable for ternary complex formation studies |
| Biochemical Standardization & Orthogonal Binding | Theoretical MW confirmed; suitable for SPR, ITC, and ATP-competition binding assay development |
Live IRAK1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for IRAK1-targeted therapeutics is intensifying, with major players shifting focus from pan-IRAK inhibitors to highly selective IRAK1-specific compounds to avoid IRAK4-related immunosuppressive toxicities. As the role of IRAK1 in MYD88-driven hematologic malignancies and auto-inflammatory disorders becomes clearer, first-generation inhibitors are advancing toward the clinic. The next wave of R&D is targeting kinase-degrader modalities (PROTACs) and resistance mutation profiling through structure-guided medicinal chemistry. Emerging evidence also supports combination regimens—pairing IRAK1 blockade with BCL-2 inhibitors in AML or with checkpoint blockade in solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Selective Small Molecule Inhibitor | Nimbus Therapeutics, Curis (emavusertib), Bayer | Autoimmune (SLE, RA), MYD88-mutant Lymphoma | Selectivity Assay (Need IRAK1 vs IRAK4 WT & mutant proteins, >95% purity) |
| PROTAC / Degrader | Kymera Therapeutics, C4 Therapeutics | Rheumatoid Arthritis, B-cell malignancies, Hidradenitis Suppurativa | Full-length Protein Engagement (Native conformation HEK293 expressed); cellular degradation assays |
| Pan-IRAK / Dual Inhibitor | Aurigene, Takeda, Academic labs | Inflammation, AML, DLBCL | Homology Panel (IRAK1, IRAK4, IRAK2, IRAK3 strict mass spec verified); combination profiling with MYD88/IRAK4 reagents |